Human iPSC-derived Midbrain Dopaminergic Neurons for Parkinson’s Disease Modeling and Cell Therapy
This record is part of
a dataset collected by the EU Commission in June-September 2018
. Some of these links will therefore die out with time.
Please see the
overview of courses maintained by ETPLAS
or contact Norecopa for more information.
Owner/Developer: Cellular Dynamics (cdi)
United States of America
15 June 2017
|Description:||Parkinson’s disease (PD) affects approximately 1% of people over the age of 65 and is the second most common neurodegenerative disorder after Alzheimer’s disease. The advent of induced pluripotent stem cell (iPSC) technology now grants us access to previously unattainable cell types in the human brain. In this presentation, we will discuss how stem cells are being used not only to study PD in the lab, but also to develop treatments for PD using cells as therapies. Specifically, we have created an isogenic disease model for PD using human iPSC-derived midbrain dopaminergic neurons and have developed in vitro assays for comparative analysis of mitochondrial bioenergetics, calcium handling, and network-level electrophysiology. In the regenerative medicine space, we are actively manufacturing cGMP HLA “superdonor” iPSC lines for universal utility and will provide an update on our progress in developing iPSC-derived cellular therapies, including our program to treat PD by engrafting human midbrain dopaminergic neurons.|
Optional / Voluntary
Students, Researchers, Regulators and policy-makers, Teachers and educators, Technicians, Managers, Scientific officers / Project managers, Professionals (e.g. veterinarians), General public
Academia, Industry, Governmental bodies, Contract Research Organizations (CROs), Consulting, SMEs
University (Bachelor), University (Master), University (Doctoral education), Postdoctoral (teaching and research), Continuing Professional Development
Full coverage (a dedicated course)
|Details on the topic or technology covered:||
Coby Carlson and Chris McMahon from Cellular Dynamics International discuss the development, manufacture and therapeutic research programs incorporating iPSC-derived dopaminergic neurons aimed at therapeutic intervention in Parkinson's disease.
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot reply to you unless you send us an email.
What are you looking for?
We value your feedback so we can improve the information on the page. Please add your email address if you would like a reply. Thank you in advance for your help.!Please contact us by email if you have any questions.